IHFB Cognacq Jay
- Address
- lock Available on a paid plan
Digestive System Cancer Research
At IHFB Cognacq Jay, clinical research in digestive system diseases focuses mainly on colorectal cancer, rectal carcinoma, colon carcinoma, and cholangiocarcinoma. These studies are designed to test new treatment strategies, compare them with current standards of care, and improve outcomes for patients with advanced or hard-to-treat disease.
- Metastatic colorectal cancer and advanced colorectal adenocarcinoma
- Locally advanced rectal cancer and localized colon cancer
- Cholangiocarcinoma with FGFR alterations
- Anal carcinoma and other gastrointestinal solid tumors
The site is also involved in research using immunotherapy, targeted therapy, and circulating tumor DNA to refine treatment selection and monitor disease control.
Breast Cancer Studies
A major part of the oncology portfolio at this hospital centers on breast cancer, especially ER+/HER2-negative breast cancer and triple-negative breast cancer. The trials aim to improve long-term disease control, reduce recurrence risk, and personalize treatment based on how well patients respond to therapy.
- Early and metastatic breast cancer
- ER+/HER2-negative high-risk disease
- Triple-negative breast cancer after surgery or neoadjuvant treatment
- Biology-guided endocrine and targeted treatment strategies
Research here includes evaluating combinations of endocrine therapy, CDK4/6 inhibitors, and immunotherapy, with a strong focus on selecting the most effective approach for each patient.
Precision Oncology and Biomarker-Guided Care
The site also contributes to precision oncology research across solid cancers, using biomarkers to guide treatment decisions and better understand which patients are most likely to benefit from specific therapies. These studies are aimed at improving response rates and extending progression-free and disease-free survival.
- Biomarker-driven treatment selection
- ctDNA-guided monitoring and adjuvant decisions
- Mutation-focused approaches in advanced cancer
- Combination strategies for difficult-to-treat solid tumors
This research reflects a broader effort to make cancer treatment more individualized, combining molecular testing with new therapeutic options to support better outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 63 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 48 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in IHFB Cognacq Jay
lock Showing 1 of 31 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) | Gilead Sciences Inc. | Phase II | Not Recruiting | Jun 2023 | Jun 2024 |
IMP list
lock Showing 1 of 63 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 16 | Unknown | 2014-12-23 | 2026-05-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.